# Evolus, Inc.: financial statements, quarterly

EOLS · Nasdaq · CIK 1570562 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eols.md) · [Financials](/companies/eols/financials.md) · [Filings](/companies/eols/filings.md) · [Insiders](/companies/eols/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eols/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [50.0](/filings/0001570562-24-000128.md) | [61.0 d](/filings/0001628280-26-014001.md) | [59.3](/filings/0001570562-25-000075.md) | [66.9](/filings/0001570562-25-000098.md) | [61.1](/filings/0001628280-25-049673.md) | [78.9 d](/filings/0001628280-26-014001.md) | [68.5](/filings/0001570562-26-000066.md) | [69.4](/filings/0001628280-26-053468.md) | [69.0](/filings/0001628280-25-049673.md) | [90.3 d](/filings/0001628280-26-014001.md) | [73.1](/filings/0001570562-26-000066.md) | [84.1](/filings/0001628280-26-053468.md) |
| Cost of revenue | $m | [15.4](/filings/0001570562-24-000128.md) | [22.2 d](/filings/0001628280-26-014001.md) | [18.8](/filings/0001570562-25-000075.md) | [19.8](/filings/0001570562-25-000098.md) | [19.0](/filings/0001628280-25-049673.md) | [26.3 d](/filings/0001628280-26-014001.md) | [21.9](/filings/0001570562-26-000066.md) | [24.1](/filings/0001628280-26-053468.md) | [23.1](/filings/0001628280-25-049673.md) | [31.0 d](/filings/0001628280-26-014001.md) | [24.2](/filings/0001570562-26-000066.md) | [26.9](/filings/0001628280-26-053468.md) |
| Gross profit | $m | not reported | not reported | [40.5](/filings/0001570562-25-000075.md) | [47.1](/filings/0001570562-25-000098.md) | [42.1](/filings/0001628280-25-049673.md) | [52.6 d](/filings/0001628280-26-014001.md) | [46.7](/filings/0001570562-26-000066.md) | [45.3](/filings/0001628280-26-053468.md) | [45.8](/filings/0001628280-25-049673.md) | [59.3 d](/filings/0001628280-26-014001.md) | [48.9](/filings/0001570562-26-000066.md) | [57.2](/filings/0001628280-26-053468.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [43.3](/filings/0001570562-24-000128.md) | [43.1 d](/filings/0001628280-26-014001.md) | [45.1](/filings/0001570562-25-000075.md) | [50.2](/filings/0001570562-25-000098.md) | [52.5](/filings/0001628280-25-049673.md) | [50.2 d](/filings/0001628280-26-014001.md) | [56.6](/filings/0001570562-26-000066.md) | [56.7](/filings/0001628280-26-053468.md) | [52.8](/filings/0001628280-25-049673.md) | [54.7 d](/filings/0001628280-26-014001.md) | [52.0](/filings/0001570562-26-000066.md) | [57.1](/filings/0001628280-26-053468.md) |
| Operating income | $m | [(13.4)](/filings/0001570562-24-000128.md) | [(8.6) d](/filings/0001628280-26-014001.md) | [(8.9)](/filings/0001570562-25-000075.md) | [(7.7)](/filings/0001570562-25-000098.md) | [(15.5)](/filings/0001628280-25-049673.md) | [(2.3) d](/filings/0001628280-26-014001.md) | [(15.2)](/filings/0001570562-26-000066.md) | [(10.2)](/filings/0001628280-26-053468.md) | [(11.5)](/filings/0001628280-25-049673.md) | [4.2 d](/filings/0001628280-26-014001.md) | [(6.8)](/filings/0001570562-26-000066.md) | [(4.5)](/filings/0001628280-26-053468.md) |
| Interest expense | $m | [3.8](/filings/0001570562-23-000115.md) | [4.1 d](/filings/0001570562-24-000041.md) | [4.7](/filings/0001570562-24-000080.md) | [4.7](/filings/0001570562-25-000098.md) | [4.8](/filings/0001628280-25-049673.md) | [4.6 d](/filings/0001628280-26-014001.md) | [4.4](/filings/0001570562-26-000066.md) | [7.2](/filings/0001628280-26-053468.md) | [4.1](/filings/0001628280-25-049673.md) | [4.0 d](/filings/0001628280-26-014001.md) | [4.0](/filings/0001570562-26-000066.md) | [4.2](/filings/0001628280-26-053468.md) |
| Income tax | $m | [0.0](/filings/0001570562-24-000128.md) | [0.1 d](/filings/0001628280-26-014001.md) | [0.0](/filings/0001570562-25-000075.md) | [0.0](/filings/0001570562-25-000098.md) | [0.1](/filings/0001628280-25-049673.md) | [0.4 d](/filings/0001628280-26-014001.md) | [0.1](/filings/0001570562-26-000066.md) | [0.1](/filings/0001628280-26-053468.md) | [0.2](/filings/0001628280-25-049673.md) | [0.4 d](/filings/0001628280-26-014001.md) | [0.3](/filings/0001570562-26-000066.md) | [(0.2)](/filings/0001628280-26-053468.md) |
| Net income | $m | [(16.9)](/filings/0001570562-24-000128.md) | [(11.8) d](/filings/0001628280-26-014001.md) | [(13.1)](/filings/0001628280-25-049673.md) | [(11.4)](/filings/0001628280-25-049673.md) | [(19.2)](/filings/0001628280-25-049673.md) | [(6.8) d](/filings/0001628280-26-014001.md) | [(18.9)](/filings/0001628280-26-053468.md) | [(17.1)](/filings/0001628280-26-053468.md) | [(15.7)](/filings/0001628280-25-049673.md) | [0.1 d](/filings/0001628280-26-014001.md) | [(10.7)](/filings/0001628280-26-053468.md) | [(8.1)](/filings/0001628280-26-053468.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001570562-24-000128.md) | not reported | [(0.22)](/filings/0001570562-25-000075.md) | [(0.18)](/filings/0001570562-25-000098.md) | [(0.30)](/filings/0001628280-25-049673.md) | not reported | [(0.30)](/filings/0001570562-26-000066.md) | [(0.27)](/filings/0001628280-26-053468.md) | [(0.24)](/filings/0001628280-25-049673.md) | not reported | [(0.16)](/filings/0001570562-26-000066.md) | [(0.12)](/filings/0001628280-26-053468.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0001570562-24-000128.md) | not reported | [(0.22)](/filings/0001570562-25-000075.md) | [(0.18)](/filings/0001570562-25-000098.md) | [(0.30)](/filings/0001628280-25-049673.md) | not reported | [(0.30)](/filings/0001570562-26-000066.md) | [(0.27)](/filings/0001628280-26-053468.md) | [(0.24)](/filings/0001628280-25-049673.md) | not reported | [(0.16)](/filings/0001570562-26-000066.md) | [(0.12)](/filings/0001628280-26-053468.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [38.7](/filings/0001570562-23-000115.md) | [62.8](/filings/0001570562-25-000020.md) | [97.0](/filings/0001570562-24-000080.md) | [93.7](/filings/0001570562-24-000116.md) | [85.0](/filings/0001570562-24-000128.md) | [87.0](/filings/0001628280-26-014001.md) | [67.9](/filings/0001570562-25-000075.md) | [61.7](/filings/0001570562-25-000098.md) | [43.5](/filings/0001628280-25-049673.md) | [53.8](/filings/0001628280-26-053468.md) | [49.8](/filings/0001570562-26-000066.md) | [45.2](/filings/0001628280-26-053468.md) |
| Current assets | $m | [92.0](/filings/0001570562-23-000115.md) | [112](/filings/0001570562-25-000020.md) | [150](/filings/0001570562-24-000080.md) | [158](/filings/0001570562-24-000116.md) | [150](/filings/0001570562-24-000128.md) | [151](/filings/0001628280-26-014001.md) | [132](/filings/0001570562-25-000075.md) | [145](/filings/0001570562-25-000098.md) | [135](/filings/0001628280-25-049673.md) | [143](/filings/0001628280-26-053468.md) | [139](/filings/0001570562-26-000066.md) | [168](/filings/0001628280-26-053468.md) |
| Total assets | $m | [168](/filings/0001570562-23-000115.md) | [189](/filings/0001570562-25-000020.md) | [226](/filings/0001570562-24-000080.md) | [234](/filings/0001570562-24-000116.md) | [230](/filings/0001570562-24-000128.md) | [233](/filings/0001628280-26-014001.md) | [213](/filings/0001570562-25-000075.md) | [229](/filings/0001570562-25-000098.md) | [219](/filings/0001628280-25-049673.md) | [226](/filings/0001628280-26-053468.md) | [221](/filings/0001570562-26-000066.md) | [248](/filings/0001628280-26-053468.md) |
| Current liabilities | $m | [48.5](/filings/0001570562-23-000115.md) | [48.3](/filings/0001570562-25-000020.md) | [46.8](/filings/0001570562-24-000080.md) | [54.1](/filings/0001570562-24-000116.md) | [60.8](/filings/0001570562-24-000128.md) | [63.0](/filings/0001628280-26-014001.md) | [56.2](/filings/0001570562-25-000075.md) | [63.8](/filings/0001570562-25-000098.md) | [66.7](/filings/0001628280-25-049673.md) | [75.3](/filings/0001628280-26-053468.md) | [68.0](/filings/0001570562-26-000066.md) | [98.7](/filings/0001628280-26-053468.md) |
| Total liabilities | $m | [187](/filings/0001570562-23-000115.md) | [210](/filings/0001570562-25-000020.md) | [208](/filings/0001570562-24-000080.md) | [214](/filings/0001570562-24-000116.md) | [224](/filings/0001570562-24-000128.md) | [227](/filings/0001628280-26-014001.md) | [220](/filings/0001570562-25-000075.md) | [247](/filings/0001570562-25-000098.md) | [248](/filings/0001628280-25-049673.md) | [249](/filings/0001628280-26-053468.md) | [249](/filings/0001570562-26-000066.md) | [279](/filings/0001628280-26-053468.md) |
| Long-term debt | $m | [95.1](/filings/0001570562-23-000115.md) | [120](/filings/0001570562-24-000041.md) | [121](/filings/0001570562-24-000080.md) | [121](/filings/0001570562-24-000116.md) | [121](/filings/0001570562-24-000128.md) | [122](/filings/0001628280-25-049673.md) | [122](/filings/0001570562-25-000075.md) | [145](/filings/0001570562-25-000098.md) | [146](/filings/0001628280-25-049673.md) | [146](/filings/0001628280-26-053468.md) | [156](/filings/0001570562-26-000066.md) | [157](/filings/0001628280-26-053468.md) |
| Shareholders' equity | $m | [(19.4)](/filings/0001570562-24-000128.md) | [(20.7)](/filings/0001628280-26-014001.md) | [18.4](/filings/0001628280-25-049673.md) | [19.3](/filings/0001628280-25-049673.md) | [5.9](/filings/0001628280-25-049673.md) | [5.5](/filings/0001628280-26-053468.md) | [(6.6)](/filings/0001628280-26-053468.md) | [(18.7)](/filings/0001628280-26-053468.md) | [(28.8)](/filings/0001628280-25-049673.md) | [(23.1)](/filings/0001628280-26-053468.md) | [(28.8)](/filings/0001628280-26-053468.md) | [(30.9)](/filings/0001628280-26-053468.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.9) d](/filings/0001570562-24-000128.md) | [0.8 d](/filings/0001628280-26-014001.md) | [(10.6)](/filings/0001570562-25-000075.md) | [(6.5) d](/filings/0001570562-25-000098.md) | [(5.7) d](/filings/0001628280-25-049673.md) | [4.8 d](/filings/0001628280-26-014001.md) | [(15.6)](/filings/0001570562-26-000066.md) | [(24.8) d](/filings/0001628280-26-053468.md) | [(14.7) d](/filings/0001628280-25-049673.md) | [12.8 d](/filings/0001628280-26-014001.md) | [(10.0)](/filings/0001570562-26-000066.md) | [(3.6) d](/filings/0001628280-26-053468.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001570562-24-000128.md) | [0.2 d](/filings/0001628280-26-014001.md) | [0.3](/filings/0001570562-25-000075.md) | [0.5 d](/filings/0001570562-25-000098.md) | [0.3 d](/filings/0001628280-25-049673.md) | [0.4 d](/filings/0001628280-26-014001.md) | [0.3](/filings/0001570562-26-000066.md) | [0.7 d](/filings/0001628280-26-053468.md) | [1.0 d](/filings/0001628280-25-049673.md) | [1.5 d](/filings/0001628280-26-014001.md) | [0.4](/filings/0001570562-26-000066.md) | [0.1 d](/filings/0001628280-26-053468.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.2](/filings/0001570562-23-000115.md) | [56.5](/filings/0001570562-24-000080.md) | [56.9](/filings/0001570562-24-000116.md) | [57.0](/filings/0001570562-24-000128.md) | [58.8](/filings/0001570562-25-000075.md) | [62.7](/filings/0001570562-25-000098.md) | [63.1](/filings/0001628280-25-049673.md) | [63.7](/filings/0001570562-26-000066.md) | [64.5](/filings/0001628280-26-053468.md) | [64.7](/filings/0001628280-25-049673.md) | [65.2](/filings/0001570562-26-000066.md) | [65.9](/filings/0001628280-26-053468.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,050,440 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053468.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.